1 Subsequently, 332 patients
died during 16 102 person-years of follow-up.
2 al without an ICD after CF-LVAD implantation
died during 276.2 months of follow-up (mean time without
3 58 397 participants
died during 3 195 484 person-years of follow-up (average
4 A total of 6344 of 37 496 patients
died during 359 219 years of follow-up.
5 e likely to exercise and had a lower risk of
dying during 5-year follow-up, with exercise mediating t
6 Of 21,484 patients identified, 12,142
died during 74,982 person-years of follow-up.
7 4 [56.5%] were male), 80 individuals (15.9%)
died during a mean (SD) follow-up of 7.8 (1.5) years.
8 Of the 187 study participants, 46
died during a mean follow-up of 23.0 months.
9 9 had an echocardiogram and 217 of 739 (29%)
died during a mean follow-up of 4.2 years.
10 Among 434 PAD participants, 103 (24%)
died during a mean follow-up of 47.6 months.
11 Thirty-five (23.3%) patients
died during a mean follow-up period of 1,016 +/- 132 day
12 Of 30,237 released inmates, 443
died during a mean follow-up period of 1.9 years.
13 6 participants developed incident HF and 468
died during a mean follow-up period of 11.2 years.
14 vents occurred, and 151,441 (32.7%) patients
died during a mean follow-up period of 18.0 months.
15 Among 1727 HIV-positive PWID, 493 (28.5%)
died during a median 5.1 years (interquartile range, 2.1
16 788 patients (13.2%)
died during a median follow-up of 3.2 years, and 26.8% p
17 ne hundred twenty-three participants (27.8%)
died during a median follow-up of 4.7 years after the 2-
18 Ten patients
died during adulthood.
19 An additional 30% of HiSen SCD mice
died during aerosolization compared with 10% in LoSen SC
20 ts who did not have hepatitis B virus or HCV
died during an average of 1.2 years of follow-up per per
21 Overall, 3% and 4% of patients
died during bortezomib-based and nonbortezomib-based ind
22 ave implications for understanding how cells
die during certain stress conditions and how such cell d
23 experienced disease progression, one patient
died during chemotherapy, and all others had stable dise
24 -eight percent (N = 16) of affected children
died during childhood (ages 7 months to 6 years) from me
25 i infection, 80% of 12/15-LOX-deficient mice
died during chronic toxoplasmosis, compared to no deaths
26 s, but fewer of the activated CD8(+) T cells
died during contraction, generating a larger pool of mem
27 a material contribution: they spontaneously
die during copulation and are subsequently eaten by fema
28 nstead, male wasp larvae were more likely to
die during development.
29 uned, and some Wld(S)-expressing cells still
died during development, in both cases detached axon fra
30 is was delayed or failed, and 50% of embryos
died during development.
31 ears and older at treatment initiation, 2270
died during dialysis treatment (38.6/1000 person-years).
32 Of those younger than 5 years, 705
died during dialysis treatment (98.8/1000 person-years);
33 How trees
die during drought over multiple years remains largely u
34 majority of adult hippocampal newborn cells
die during early differentiation from intermediate proge
35 Because DSG2 knockouts
die during early embryogenesis, mice were prepared with
36 Hausp knockout mice
die during early embryonic development between embryonic
37 that homozygous Zip4-knockout mouse embryos
die during early morphogenesis and heterozygous offsprin
38 Almost all Armc5 knockout mice
died during early embryonic development, around 6.5 and
39 us kinase-dead mutations in Atm (Atm(KD/KD))
died during early embryonic development.
40 UBR4-deficient mice
die during embryogenesis and exhibit pleiotropic abnorma
41 tions, and Cdk2(-/-) Cdk4(-/-) p53(-/-) mice
die during embryogenesis at embryonic day 13.5.
42 Mice lacking Ctr1
die during embryogenesis from widespread developmental d
43 Here we show that mice deficient for ABIN-1
die during embryogenesis with fetal liver apoptosis, ana
44 FBXL5-null mice
die during embryogenesis, although viability is restored
45 difficult to study because Acvr1b(-/-) mice
die during embryogenesis.
46 t in the mouse and reported that homozygotes
die during embryogenesis.
47 In the 129SvImJ background, UBR3-/- mice
died during embryogenesis, whereas the C57BL/6 backgroun
48 Mice lacking DNase II
die during embryonic development through comparable infl
49 Calr null mice
die during embryonic development, rendering indeterminat
50 e Caenorhabditis elegans cells programmed to
die during embryonic development.
51 her ENU mutation (or compound heterozygotes)
died during embryonic development at 9.5-14.5 days post
52 Most zooxanthellar phylotypes are
dying during expulsion upon release from the host.
53 ents engaged in exercise were less likely to
die during follow-up (hazard ratio, 0.50; 95% confidence
54 Xpert-negative patients were less likely to
die during follow-up.
55 Three donors
died during follow-up (0.6-4.9 years) as a result of the
56 Eight patients
died during follow-up (2 sudden unexpected and 6 noncard
57 Forty-nine patients
died during follow-up (22 type A, 27 type B), 31 suddenl
58 g 2,315 participants diagnosed with CRC, 966
died during follow-up (413 from CRC and 176 from cardiov
59 urvived at least 90 d after discharge, 17.4%
died during follow-up (AKI 29.8%, without AKI 16.1%).
60 Overall, 157 patients (3%)
died during follow-up (all-cause mortality, 11.2/1000 PY
61 om the trial 240 days after enrolment and 12
died during follow-up (five in the intervention group; s
62 Two hundred eighty-six patients (52%)
died during follow-up (mean follow-up 4.8 yr).
63 hemodialysis patients, 5088 (17.8%) of whom
died during follow-up (median 365 d).
64 Fifteen of 57 patients
died during follow-up (n=8 with RCD I and n=7 with RCD I
65 lity; 81% of patients in the highest tertile
died during follow-up (OR, 6.3 relative to lowest tertil
66 Participants who
died during follow-up appeared to have profiles of multi
67 Overall, 42 patients (12.1%)
died during follow-up as a result of cancer progression.
68 51 (16%) of the cohort
died during follow-up from study entry (10 years after c
69 Four patients
died during follow-up with a 5-year survival rate 99.5%
70 Among the 1470 patients who
died during follow-up, 87% had EOL care discussions, com
71 Seven patients with MHSs
died during follow-up, all due to PNETs, including 4 pat
72 Overall, 65 936 of the full sample
died during follow-up, and 22 152 died from heart diseas
73 6155 (8.8%) people with epilepsy
died during follow-up, at a median age of 34.5 (IQR 21.0
74 nts with documented EOL care discussions who
died during follow-up, discussions took place a median o
75 Of those, 48 patients
died during follow-up, including 18 because of CHF progr
76 l of 949 participants with colorectal cancer
died during follow-up, including 408 from colorectal can
77 the 2,548 colorectal cancer survivors, 1,074
died during follow-up, including 453 as a result of colo
78 Twelve patients (25%)
died during follow-up, mostly from heart failure (50%).
79 g 6,721 years of follow-up, 194 participants
died during follow-up, resulting in a crude mortality ra
80 Twenty-two percent of the cohort
died during follow-up, which began at the time of leavin
81 A total of 15,138 men and 10,087 women
died during follow-up, which ended in 2008.
82 g the 27 619 current cigarette smokers, 4224
died during follow-up, with 1130 deaths attributed to CV
83 Overall, 59% of the women
died during follow-up, with 95% of deaths resulting from
84 s was 57 years, and 59 (21%) of the patients
died during follow-up, with a median follow-up of 59 mon
85 red retransplantation and 208 patients (22%)
died during follow-up.
86 A total of 117 (22%) patients
died during follow-up.
87 Of 608 patients enrolled, 237
died during follow-up.
88 One patient (in the fluorouracil group)
died during follow-up.
89 Of the 444 patients with lung cancer, 318
died during follow-up.
90 e was 1.8 years (range, 0.1-78); 111 (10.2%)
died during follow-up.
91 ischemic cerebrovascular disease, and 3,807
died during follow-up.
92 e, 50-71 years]) in the study, 21123 (21.3%)
died during follow-up.
93 4/718 (9%) lost their graft, and 50/718 (7%)
died during follow-up.
94 Overall, 34.6% of these patients
died during follow-up.
95 he AN1792 group, three in the placebo group--
died during follow-up.
96 Seventy-six patients (20%)
died during follow-up.
97 ined for a random sample of 40% of those who
died during follow-up.
98 One hundred twenty-seven patients (28.6%)
died during follow-up.
99 Fifty-five participants (18.2%)
died during follow-up.
100 rders 0-3 months postpartum, and 96 of these
died during follow-up.
101 A total of 6,206 patients (9%)
died during follow-up.
102 A total of 118 patients
died during follow-up.
103 Fourteen patients
died during follow-up: 11 in the brachytherapy arm vs 3
104 Fifty percent of patients
died during follow-up: 25% died of disease, 24% died of
105 A total of 3073 participants (6%)
died during follow-up; 78% of these deaths were attribut
106 n group and three in the peer-support group)
died during follow-up; these deaths were deemed unrelate
107 low vitamin D level had a 61% higher risk of
dying during follow-up (95% CI, 25%-107%).
108 week) had a significantly increased risk of
dying during follow-up (HR=1.27, 95% CI 1.22-1.31).
109 e probability of developing cirrhosis and of
dying during follow-up using Cox proportional hazards mo
110 Odds of
dying during follow-up were 8.5-fold higher in patients
111 igands received prolonged IL-7 signaling and
died during homeostasis.
112 usion and 16 (17%) assigned to standard care
died during hospital stay.
113 06 and who did not have baseline dementia or
die during hospitalization (n = 164,661) were identified
114 ntly more likely than uninfected patients to
die during hospitalization after admission for AMI or st
115 ntly more likely than uninfected patients to
die during hospitalization after admission for AMI or st
116 A small percentage of patients
die during hospitalization or shortly thereafter, and it
117 In the hospital cohort, 72 (29.4%) patients
died during hospitalization and 40 (36.0%) patients died
118 onfirmed underuse of echo among patients who
died during hospitalization for indications identified i
119 evere head or pelvic injuries, and those who
died during hospitalization were excluded.
120 Among patients who
died during hospitalization, a group whose disease sever
121 Thirty percent
died during hospitalization, and 6 patients were dischar
122 I, 0.7%-1.2%) of the orally treated patients
died during hospitalization, whereas 10.9% (95% CI, 10.7
123 Two hundred seventeen patients (39%)
died during hospitalization, whereas another 69 patients
124 Overall, 40 (17%) patients
died during hospitalization.
125 east 1 antimicrobial agent, of whom 52 (14%)
died during hospitalization.
126 Eight (0.7%) RSV-infected study patients
died during hospitalization.
127 Approximately 14% of the ICC patients
died during hospitalization.
128 Sixty-six patients (38.1%)
died during hospitalization.
129 5 years old were enrolled; 107 (9%) children
died during hospitalization.
130 One hundred twenty-seven (23.1%)
died during hospitalization.
131 34 patients had microbiologic failure and 25
died during hospitalization.
132 eveloped had a significantly greater risk of
dying during hospitalization (65.4%) than those who did
133 Although the likelihood of
dying during hospitalization was greater among patients
134 38%) completed induction therapy: 7 patients
died during induction therapy, 8 had disease progression
135 ieved in 153/180 (85%) patients and 27 (15%)
died during induction.
136 Fgfr1(Delta)Frs/DeltaFrs embryos
die during late embryogenesis, and exhibit defects in ne
137 alization, whereas another 69 patients (12%)
died during later follow-up.
138 n participants were separated into those who
died during Medicare follow-up and those who survived.
139 ronectin (FN) and osteopontin expression and
died during mesoderm development akin to FAK kinase-dead
140 odomain sites show loss of BMP4 function and
die during mid-embryogenesis.
141 Most Dmap1(+/+) progeny
died during midgestation, with loss of DNA methylation o
142 knockdown increased the ratio of cells that
died during mitotic arrest and sensitized cancer cells t
143 lar to that at which endogenous interneurons
died during normal development.
144 Eighteen patients
died during or shortly after surgery leaving 637 patient
145 Two patients
died during phase 1 and none during phase 2.
146 in determining the fate of cells to live or
die during physiological processes such as embryonic dev
147 Two patients
died during postoperative therapy, one from infection (a
148 (50.8%) of the women of known HIV status who
died during pregnancy or post partum were HIV infected.
149 a systematic review of the relative risk of
dying during pregnancy for HIV-positive women compared w
150 s of the TIP60-p400 complex, Dmap1(-/-) mice
died during preimplantation in both Dnmt1(+/+) and Dnmt1
151 ere alive at the outset of the NVVLS, and 81
died during recruitment; 1450 of the remaining 1839 (78.
152 For patients at a different hospital, 13.7%
died during rehospitalization versus 11.1% who died at t
153 hese data demonstrate that mice predicted to
die during sepsis have no significant lung injury.
154 D (the patient, who was exercise restricted,
died during sleep), for an incidence of 0.18/1,000 patie
155 plantation (15/142 versus 1/147; P<0.001) or
die during study follow-up period (7 versus 0; P=0.007).
156 Eight patients (4.2%) receiving ET-B
died during study or within 30 days of end of treatment.
157 Among 375,629 patients, 107,634
died during study period, of which 54,759 (50.87%) death
158 Four patients
died during study treatment or within 30 days of last do
159 ients survived the FT procedure, one patient
died during subsequent revisions procedures for sepsis.
160 notified with TB over the study period, <1%
died during TB treatment and 89.5% were cured or complet
161 uring the inflammatory phase are destined to
die during termination of the immune response.
162 insights, it is still unclear how RPE cells
die during the course of the disease.
163 eous synaptic currents and are more prone to
die during the critical period when adult-born neurons a
164 The Coup-tfII-null mutant mice
die during the early embryonic development because of an
165 al, 1.41-12.6, P = .01), were more likely to
die during the first 8 weeks of remission induction ther
166 In nature, most juveniles
die during the first dry season, so that their harvest j
167 educed levels of afferent input and begin to
die during the first postnatal week.
168 ing graft as compared with those who did not
die during the follow-up period (TNF-alpha: median, 1.92
169 Up to 14% of Malawian adults
die during the intensive phase of tuberculosis treatment
170 and 36.7 times, respectively, more likely to
die during the neonatal period.
171 presence of suicidal ideation with intent to
die during the past week and/or a suicide attempt within
172 e polycomb group gene member Yin-Yang1 (YY1)
die during the peri-implantation stage.
173 cPGES/p23(-/-) pups
die during the perinatal period and display retarded lun
174 esized that children would be more likely to
die during the period several months before their mother
175 .51, p=<.05), if the patient was expected to
die during the shift (F(1,155)=89.67, p=<.01) and if the
176 or were admitted to a nursing home and 9.7%
died during the 1-year follow-up period.
177 45 patients
died during the 10-year follow-up.
178 bits between 1998 and 2000, a total of 3,251
died during the 13-year follow-up.
179 2)), 18% were obese (BMI >/=30 kg/m(2)), 48%
died during the 14-year follow-up, and 27% had ADL and 4
180 l of 851 participants with colorectal cancer
died during the 16-year follow-up period, including 380
181 fection, mainly those born during 1945-1964,
died during the 2006-2010 five-year period.
182 174 participants
died during the 23 years of follow-up (121 in the interv
183 Three patients (13%)
died during the 30 day follow-up.
184 Fourteen percent of subjects
died during the 30-day follow-up period.
185 3909 of the 49,731 D:A:D study participants
died during the 308,719 person-years of follow-up (crude
186 e of the tsunami and an additional 95 people
died during the 38-month follow-up period.
187 ients who underwent randomization, 1 patient
died during the 5-year follow-up period; 134 of the rema
188 nts did not provide follow-up data: 21 (24%)
died during the 6-month follow-up period, and 17 (19%) d
189 participants (8.6%) in the L-arginine group
died during the 6-month study period vs none in the plac
190 Four patients (9%)
died during the acute disease, but most showed marked im
191 937 person-years of observation), 110 (1.1%)
died during the average follow-up of 9.7 years.
192 % of people in the lowest wellbeing quartile
died during the average follow-up period of 8.5 years co
193 ts (16%) randomized to frequent hemodialysis
died during the combined trial and post-trial observatio
194 11 patients
died during the core 12-month treatment phase or up to 5
195 d deaths were recorded but 16 (62%) patients
died during the course of follow-up.
196 Two patients
died during the course of the trial, one each from laryn
197 A total of 16 patients with GVHD
died during the entire follow-up.
198 influenza in 1918-19 killed more people than
died during the entire war, showing how much remained be
199 Two patients
died during the event, neither of whom had known valve i
200 ority of larvae injected with, or fed, dsRNA
died during the final larval stage prior to pupation.
201 Eighty-three percent of OVA/OT-I mice
died during the first 2 wk of life due to multiple organ
202 atients treated in designated trauma centers
died during the first 24 hours of hospitalization.
203 Infants who had major congenital anomalies,
died during the first 3 days of life, or had missing dat
204 ty was 30% (176 patients); 76 patients (13%)
died during the first 48 hours.
205 Ten patients
died during the first 6 months after transplantation, al
206 =0.005), and more patients in the R-FC group
died during the first remission (10% vs. 4%).
207 d to participate (3 patients), and those who
died during the first year (35 patients).
208 summary score within the highest percentile
died during the first year of follow-up, indicating prom
209 Fifty-six patients assigned to TX/CEX
died during the follow-up compared with 75 of patients a
210 After censoring cases in which patients
died during the follow-up period and adjusting for month
211 Eighteen patients (64%)
died during the follow-up period ranging from 6 to 230 m
212 Forty-six percent of the cases
died during the follow-up period, compared with 13.0% of
213 % confidence interval, 204-577); 19 patients
died during the follow-up period.
214 f the 547 lung cancer patients, 412 patients
died during the follow-up.
215 patients with SLE, but none of the children,
died during the followup.
216 Four patients
died during the full follow-up, two of breast cancer-rel
217 METHODS/Ninety-one patients
died during the hospital stay while 92 patients from the
218 ging was performed in 36 patients (1 patient
died during the hospital stay).
219 of patients, and nearly half of the patients
died during the hospitalization period.
220 escents who did not have their sex recorded,
died during the index admission, had no valid discharge
221 Fourteen patients (0.1%)
died during the index hospitalization and were excluded
222 Those who
died during the index hospitalization or who had an addi
223 Of 416,997 patients, 3.8%
died during the initial SNF stay, 28.6% required readmis
224 ix were treated, six were controls, and four
died during the ischemic intervention.
225 ypertension were identified, and 23 patients
died during the mean follow-up of 32+/-14 months.
226 131 (46%) patients
died during the mean follow-up period of 5.9 years (5.3)
227 12,123 children included for analysis, 1600
died during the median follow-up of 7.1 years.
228 or decompensated cirrhosis, 61% (504 of 830)
died during the median follow-up period of 2.26 years.
229 Two varenicline-group participants
died during the nontreatment phase.
230 ine participants in the slowest HRR quartile
died during the observation period compared with 14 part
231 ean follow-up was 2.3 years and 214 patients
died during the observation period.
232 Nineteen patients
died during the observation period.
233 Overall, 2385 of the 3957 patients (60.3%)
died during the observation period: 1812 (57.4%) patient
234 hildren aged </= 5 y who commenced chelation
died during the period studied, with lead poisoning a pr
235 % had coronary artery bypass surgery, and 3%
died during the readmission.
236 Of the remaining 24, 3 (13%)
died during the same hospitalization.
237 han the 315 (9.0%) matched noncaregivers who
died during the same period.
238 Ten women
died during the study (0.61% per year).
239 41 (7%) treated patients
died during the study (15 [7%], 15 [7%], 11 [5%]); the m
240 Two (3%) patients in the 30 mg group
died during the study (pulmonary artery thrombosis and c
241 Three patients
died during the study (two because of disease progressio
242 No patients
died during the study as a result of toxic effects.
243 11 participants
died during the study follow-up period (six in the 9vHPV
244 ears, the survival rate was 97%; one patient
died during the study from a nonhematologic cause.
245 Four patients
died during the study from fatal adverse events judged t
246 Two patients
died during the study period, 1 in each treatment group.
247 22 (46%) patients
died during the study period, all from metastatic renal-
248 ecruited; 19 completed 6 months follow-up, 6
died during the study period, and 5 completed part of th
249 Thirty-four (46.6%) patients
died during the study period.
250 A total of 47 patients (55.3%)
died during the study period.
251 A total of 625 patients (35%)
died during the study period.
252 None of the infants
died during the study period.
253 s in 3-mo intervals, and 246 (4.3%) children
died during the study period.
254 imated treatment effects in participants who
died during the study were a mean (SE) of 8.6 (3.6) for
255 the cause of death in over 40% of those who
died during the study, and the mortality increased marke
256 22 patients
died during the study, and three deaths were related to
257 Seven (7%) patients
died during the study, but none of the deaths was drug r
258 Three patients
died during the study, but the deaths were not deemed to
259 93 patients (3% of the full analysis set)
died during the study, of which one death (in the denosu
260 Four patients, all in the 110 mg cohort,
died during the study, of which two might have been rela
261 nts with evaluable images, 68 patients (38%)
died during the study, were autopsied, and had neuritic
262 major bleeding was recorded, and no patient
died during the study.
263 Two patients
died during the study.
264 up for survivors was 25 months, and 21 (47%)
died during the study.
265 No patients
died during the study.
266 and 29 (6%) in the heparin-impregnated group
died during the study.
267 One patient in each group
died during the study.
268 11 (12%) of 95 patients
died during the study: eight with relapsed or refractory
269 23 (31%) patients
died during the study; none of these deaths were deemed
270 Three patients
died during the study; none of these deaths were judged
271 eight individuals (7.3%; 95% CI, 4.9%-10.4%)
died during the training period; all deaths were related
272 d five (4%) of 113 in the chemotherapy group
died during the treatment period (from the day of the fi
273 A total of 62 patients
died during the trial (24 from Hodgkin's lymphoma), for
274 123 (2%) people
died during the trial, 65 assigned vitamin D and 58 allo
275 Ten participants
died during the trial.
276 No participants
died during the trial; 81 serious adverse events were re
277 edian MELD score 7.9 vs. 11.4), and only one
died during the trials.
278 ggesting that virus-infected individuals had
died during the winter.
279 Males had a risk of
dying during the follow up that was 1.18 (95% CI 1.01-1.
280 er and survived on the basis of maternal Smn
dying during the second week of larval development.
281 tay (median, 31 d vs 13 d; p < 0.01), and to
die during their hospital stay (34% vs 23%; odds ratio,
282 f suicide among persons who had a parent who
died during their childhood.
283 Twelve percent (n = 333)
died during their hospital stay, 8.1% (n = 222) of patie
284 Twenty-seven patients (26.0%)
died during their hospital stay, and 24 of them had posi
285 s at a tertiary care university hospital who
died during their hospitalization from 2005 to 2014.
286 Of the 229 patients who
died during their hospitalization, 149 (65.0%) had sepsi
287 hundred seventeen of 331 (35.3%) inpatients
died during their hospitalization.
288 Two hundred twenty-four patients (51.4%)
died during their hospitalization.
289 Approximately one in five patients
died during their hospitalization.
290 he conventional oxygen therapy group (20.2%)
died during their ICU stay (absolute risk reduction [ARR
291 tio = 0.52) in 18 of 389 (4.6%) patients who
died during their in-hospital stay.
292 ravenous colistin for >3 consecutive days or
died during therapy (termed colistin cases).
293 reatment start, suggesting that patients who
die during this time comprise a qualitatively distinct g
294 One patient
died during treatment (unknown cause), and 12 other pati
295 Two patients who
died during treatment had pre-existing contributory diso
296 Five (2%) patients
died during treatment in each group.
297 16 (12%) patients
died during treatment or within 31 days of the last dose
298 Three (8%) patients
died during treatment, including one individual who died
299 Twenty-six XDR-TB cases (35%)
died during treatment, of whom 21 (81%) were known to be
300 Three of the patients
died during treatment.